Phase Ii Trial Of The Dual Igf-1r/Ir Inhibitor Bms-754807 With Or Without Letrozole In Aromatase Inhibitor-Resistant Breast Cancer.

Paul Haluska,A. Dhar,Xiaonan Hou,F. Huang, D. S. A. Nuyten,J. Park,A. H. Brodie,J. N. Ingle,Joan M. Carboni,Marco M. Gottardis,A. C. Wolff,Friedrich Graf Finckenstein

JOURNAL OF CLINICAL ONCOLOGY（2011）

引用 7|浏览23

暂无评分

摘要

TPS111 Background: Resistance to endocrine therapy in breast cancer is a major clinical problem. Evidence shows that insulin-like growth factor (IGF) pathway signaling contributes to tamoxifen resi...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要